文献速递运动医学关节外科

糖原合成酶激酶-3抑制剂CHIR99021减少肩袖撕裂后脂肪浸润和肌肉萎缩:一项体外实验与小鼠模型研究

The Glycogen Synthase Kinase-3 Inhibitor CHIR99021 Reduces Fatty Infiltration and Muscle Atrophy After Rotator Cuff Tears: An In Vitro Experiment and In Vivo Mouse Model.
PubMed 文献 · Am J Sports Med · 2025-02-24

研究对6例慢性全层肩袖撕裂患者的冈上肌活检标本行RNA测序,发现Akt/GSK-3通路在脂肪积累少的样本中富集。体外实验显示CHIR99021抑制纤维脂肪祖细胞成脂分化并促进C2C12成肌分化;小鼠肩袖撕裂模型中,CHIR99021腹腔注射组较溶剂对照组油红O染色减少、横截面积增大、肌肉重量丢失减少。

要点

  • RNA测序显示Akt/GSK-3通路在脂肪积累少的患者冈上肌标本及纤维脂肪祖细胞中富集。
  • CHIR99021在体外抑制纤维脂肪祖细胞成脂分化并促进C2C12成肌分化。
  • 小鼠肩袖撕裂模型中CHIR99021减少脂肪浸润和肌肉萎缩,并上调IL-6和IL-15表达。

核心结论

  • Akt/GSK-3通路在脂肪积累少的冈上肌标本和纤维脂肪祖细胞中富集,提示其可作为治疗靶点。
  • GSK-3抑制剂CHIR99021在体外和小鼠模型中可减轻肩袖撕裂后的脂肪浸润和肌肉萎缩。

研究设计与样本

  • 控制性实验室研究,对6例慢性全层肩袖撕裂患者的冈上肌活检标本行RNA测序。
  • 体外培养纤维脂肪祖细胞或C2C12成肌细胞并给予不同剂量CHIR99021,评估成脂或成肌分化。
  • 对纤维脂肪祖细胞给予或不给予CHIR99021后行RNA测序鉴定细胞通路。
  • 建立小鼠肩袖撕裂模型(离断冈上肌腱),术后腹腔注射或不注射CHIR99021,于术后1周和4周行组织学和基因表达分析评估肌肉萎缩和脂肪浸润。

主要发现

  • RNA测序分析显示Akt/GSK-3信号通路在脂肪积累最少的患者样本和纤维脂肪祖细胞中明显上调。
  • CHIR99021抑制纤维脂肪祖细胞的成脂分化并促进C2C12细胞的成肌分化。
  • 小鼠肩袖撕裂模型中,CHIR99021组较溶剂对照组冈上肌油红O染色减少、横截面积增大、肌肉重量丢失减少。
  • 基因表达分析显示术后1周和4周CHIR99021组成肌增加、脂肪浸润减少。
  • 术后1周CHIR99021组IL-6和IL-15表达水平较对照组升高。

临床怎么用

  • 作者指出GSK-3抑制剂CHIR99021显示出治疗肩袖撕裂后肌肉退变的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rotator cuff tears (RCTs) can cause inflammation, muscle atrophy, and irreversible fatty infiltration, resulting in poor clinical outcomes. Effective therapeutic approaches to inhibit fatty infiltration in rotator cuff muscles remain limited. PURPOSE: To identify pathways associated with fatty infiltration through RNA sequencing and to evaluate the therapeutic potential of the glycogen synthase kinase-3 (GSK-3) inhibitor CHIR99021 based on enrichment of the Akt/GSK-3 pathway identified by RNA sequencing. STUDY DESIGN: Controlled laboratory study. METHODS: Supraspinatus muscle biopsy specimens from 6 patients with chronic full-thickness RCTs were analyzed by RNA sequencing. Fibro-adipogenic progenitors (FAPs) or C2C12 myoblasts were cultured with different doses of CHIR99021 to assess their effects on adipogenic or myogenic differentiation, respectively. RNA sequencing identified cellular pathways in FAPs treated with or without CHIR99021. A mouse RCT model was established by detaching the supraspinatus tendon, followed by treatment with or without CHIR99021 administered intraperitoneally. Muscle atrophy and fatty infiltration were assessed histologically and through gene expression analysis at 1 and 4 weeks after surgery. RESULTS: RNA sequencing analysis identified a marked upregulation of the Akt/GSK-3 signaling pathway specifically in patients' samples and FAPs with minimal fat accumulation. CHIR99021 suppressed adipogenic differentiation in FAPs and promoted myogenic differentiation in C2C12 cells. In the mouse RCT model, CHIR99021-treated mice exhibited reduced Oil Red O staining, a larger cross-sectional area, and less muscle weight loss in the supraspinatus muscle compared with the vehicle-treated mice. Gene expression analysis indicated increased myogenesis and reduced fatty infiltration at 1 and 4 weeks after surgery as well as increased expression levels of IL-6 and IL-15 in the CHIR99021 group compared with the control group at 1 week after surgery. CONCLUSION: The Akt/GSK-3 pathway was enriched in supraspinatus muscle samples and FAPs with low fat accumulation, highlighting its potential as a therapeutic target. The GSK-3 inhibitor CHIR99021 was shown to alleviate fatty infiltration and muscle atrophy after RCTs in vitro and in vivo in a mouse model. CLINICAL RELEVANCE: The GSK-3 inhibitor CHIR99021 shows potential for treating muscle degeneration after RCTs.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Zhang P, Zhou M, Zhu Y, et al. The Glycogen Synthase Kinase-3 Inhibitor CHIR99021 Reduces Fatty Infiltration and Muscle Atrophy After Rotator Cuff Tears: An In Vitro Experiment and In Vivo Mouse Model. Am J Sports Med. 2025. PMID: 39989144. doi:10.1177/03635465251319549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。